Is there a preferable DES in diabetic patients? A critical appraisal of the evidence

Catheterization and Cardiovascular Interventions

Volumn 72, Issue 7, 2008, Pages 944-949

  Byrne, Robert A ^a   Kastrati, Adnan ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Diabetes; Percutaneous coronary intervention; Quantitative coronary angiography; Restenosis

Indexed keywords

ANTITHROMBOCYTIC AGENT; EVEROLIMUS; INSULIN; PACLITAXEL; RAPAMYCIN; ZOTAROLIMUS;

ANGIOCARDIOGRAPHY; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG ELUTING STENT; EDITORIAL; EVIDENCE BASED MEDICINE; FOLLOW UP; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; IMPLANTATION; IN-STENT RESTENOSIS; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCUTANEOUS CORONARY INTERVENTION; REGISTER; SAFETY; THROMBOSIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR AGENTS; CORONARY RESTENOSIS; CORONARY STENOSIS; DIABETES COMPLICATIONS; DRUG-ELUTING STENTS; EVIDENCE-BASED MEDICINE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; META-ANALYSIS AS TOPIC; METALS; PACLITAXEL; PATIENT SELECTION; PROSTHESIS DESIGN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGISTRIES; RISK ASSESSMENT; SIROLIMUS; THROMBOSIS; TREATMENT OUTCOME;

EID: 55749106625     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.21731     Document Type: Editorial

References (25)

1. CDC. 2005. National diabetes fact sheet: General information and national estimates on diabetes in the United States. Available at http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2005.pdf. Accessed June 22, 2008.
2. Smith SC Jr, Faxon D, Cascio W, Schaff H, Gardner T, Jacobs A, Nissen S, Stouffer R. Prevention Conference VI: Diabetes and cardiovascular disease: Writing Group VI: Revascularization in diabetic patients. Circulation 2002;105:e165-e169.
3. Sabate M, Jimenez-Quevedo P, Angiolillo DJ, Gomez-Hospital JA, Alfonso F, Hernandez-Antolin R, Goicolea J, Banuelos C, Escaned J, Moreno R, Fernandez C, Fernandez-Aviles F, Macaya C. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: The diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation 2005;112:2175-2183.
4. Ortolani P, Balducelli M, Marzaroli P, Piovaccari G, Menozzi A, Guiducci V, Sangiorgio P, Tarantino F, Geraci G, Castriota F, Tondi S, Saia F, Cooke RM, Guastaroba P, Grilli R, Marzocchi A, Maresta A. Two-year clinical outcomes with drug-eluting stents for diabetic patients with de novo coronary lesions: Results from a real-world multicenter registry. Circulation 2008; 117:923-930.
5. Moussa I, Leon MB, Baim DS, O'Neill WW, Popma JJ, Buchbinder M, Midwall J, Simonton CA, Keim E, Wang P, Kuntz RE, Moses JW. Impact of sirolimus-eluting stents on outcome in diabetic patients: A SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 2004;109: 2273-2278.
6. Hermiller JB, Raizner A, Cannon L, Gurbel PA, Kutcher MA, Wong SC, Russell ME, Ellis SG, Mehran R, Stone GW. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: The TAXUS-IV trial. J Am Coll Cardiol 2005;45:1172-1179.
7. Iijima R, Ndrepepa G, Mehilli J, Markwardt C, Bruskina O, Pache J, Ibrahim M, Schomig A, Kastrati A. Impact of diabetes mellitus on long-term outcomes in the drug-eluting stent era. Am Heart J 2007;154:688-693.
8. Wessely R, Schomig A, Kastrati A. Sirolimus and Paclitaxel on polymer-based drug-eluting stents: similar but different. J Am Coll Cardiol 2006;47:708-714.
9. Schomig A, Dibra A, Windecker S, Mehilli J, Suarez de Lezo J, Kaiser C, Park SJ, Goy JJ, Lee JH, Di Lorenzo E, Wu J, Juni P, Pfisterer ME, Meier B, Kastrati A. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol 2007;50:1373-1380.
10. Carter AJ. TOR of the cell cycle: Are there important implications for diabetics in the era of the drug-eluting stent? Catheter Cardiovasc Interv 2004;61:233-236.
11. Dibra A, Kastrati A, Mehilli J, Pache J, Schuhlen H, von Beckerath N, Ulm K, Wessely R, Dirschinger J, Schomig A. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005;353:663-670.
12. Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, Hong MK, Kim HS, Ko JK, Park JH, Lee JH, Choi SW, Seong IW, Cho YH, Lee NH, Kim JH, Chun KJ, Park SJ. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients). J Am Coll Cardiol 2008;51: 1181-1187.
13. Tomai F, Reimers B, De Luca L, Galassi AR, Gaspardone A, Ghini AS, Ferrero V, Favero L, Gioffre G, Prati F, Tamburino C, Ribichini F. Head-to-head comparison of sirolimus- and paclitaxel-eluting stent in the same diabetic patient with multiple coronary artery lesions: A prospective, randomized, multicenter study. Diabetes Care 2008;31:15-19.
14. Stankovic G, Cosgrave J, Chieffo A, Iakovou I, Sangiorgi G, Montorfano M, Airoldi F, Carlino M, Michev I, Finci L, Colombo A. Impact of sirolimus-eluting and Paclitaxel-eluting stents on outcome in patients with diabetes mellitus and stenting in more than one coronary artery. Am J Cardiol 2006;98:362-366.
15. Buch AN, Javaid A, Steinberg DH, Roy P, Pinto Slottow TL, Xue Z, Smith K, Suddath WO, Satler LF, Kent KM, Pichard AD, Waksman R. Outcomes after sirolimus- and paclitaxel-eluting stent implantation in patients with insulin-treated diabetes mellitus. Am J Cardiol 2008;101:1253-1258.
16. Daemen J, Garcia-Garcia HM, Kukreja N, Imani F, de Jaegere PP, Sianos G, van Domburg RT, Serruys PW. The long-term value of sirolimus- and paclitaxel-eluting stents over bare metal stents in patients with diabetes mellitus. Eur Heart J 2007; 28:26-32.
17. Billinger M, Beutler J, Taghetchian KR, Remondino A, Wenaweser P, Cook S, Togni M, Seiler C, Stettler C, Eberli FR, Luscher TF, Wandel S, Juni P, Meier B, Windecker S. Two-year clinical outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents in diabetic patients. Eur Heart J 2008; 29:718-725.
18. Austin PC, Grootendorst P, Anderson GM. A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med 2007;26:734-753.
19. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:989-997.
20. Stettler C, Allemann S, Wandel S, Kastrati A, Morice MC, Schömig A, Pfisterer ME, Stone GW, Leon MB, Lezo JSd, Goy J-J, Park S-J, Sabaté M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Carlo MD, Erglis A, Chechi T, Schalij POJ, Diem P, Meier B, Windecker S, Jüni P. Drug-eluting versus bare-metal stents in diabetic patients: Collaborative Network Meta-Analysis. BMJ (in press).
21. Stettler C, Allemann S, Egger M, Windecker S, Meier B, Diem P. Efficacy of drug eluting stents in patients with and without diabetes mellitus: Indirect comparison of controlled trials. Heart 2006;92:650-657.
22. Pocock SJ. Safety of drug-eluting stents: demystifying network meta-analysis. Lancet 2007;370:2099-2100.
23. Kumbhani DJ, Bavry AA, Kamdar AR, Helton TJ, Bhatt DL. The effect of drug-eluting stents on intermediate angiographic and clinical outcomes in diabetic patients: Insights from randomized clinical trials. Am Heart J 2008;155:640-647.
24. Gandhi GY, Murad MH, Fujiyoshi A, Mullan RJ, Flynn DN, Elamin MB, Swiglo BA, Isley WL, Guyatt GH, Montori VM. Patient-important outcomes in registered diabetes trials. JAMA 2008;299:2543-2549.
25. Pocock SJ, Lansky AJ, Mehran R, Popma JJ, Fahy MP, Na Y, Dangas G, Moses JW, Pucelikova T, Kandzari DE, Ellis SG, Leon MB, Stone GW. Angiographic surrogate end points in drug-eluting stent trials: A systematic evaluation based on individual patient data from 11 randomized, controlled trials. J Am Coll Cardiol 2008;51:23-32.